id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-280932-xhz5d4ty	Acanfora, Domenico	Sacubitril/valsartan in COVID-19 patients: the need for trials	2020-05-05		.txt	text/plain	823	44	40	6 Moreover, post-hoc analysis from the Comparison of Sacubitril-Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode (PIONEER-HF) trial revealed a 42% relative risk reduction in the composite endpoint of death from any cause, re-hospitalization for heart failure, left ventricular assist device implantation, or listing for cardiac transplant, a 42% relative risk reduction in the composite endpoint of cardiovascular death or re-hospitalization for heart failure, and a 39% relative risk reduction in re-hospitalization for heart failure after 8 weeks of treatment with sacubitril/valsartan administered early in patients stabilized during hospitalization for acute decompensated heart failure. Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan) Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF Trial	./cache/cord-280932-xhz5d4ty.txt	./txt/cord-280932-xhz5d4ty.txt